TME Pharma NV

ALTME

Company Profile

  • Business description

    TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).

  • Contact

    Max-Dohrn-Street 8-10
    Berlin10589
    DEU

    T: +49 30166370820

    https://www.tmepharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    13

Stocks News & Analysis

stocks

New ASX share on our best ideas list

This undervalued miner is unappreciated by the market.
stocks

Has the most hated company on the ASX 200 bounced back?

Encouraging results indicate a potential turnaround story.
stocks

Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown

We think Amazon stock looks attractive.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,922.004.900.05%
CAC 407,632.0185.851.14%
DAX 4023,757.69331.721.42%
Dow JONES (US)44,144.62556.041.28%
FTSE 1009,128.3059.720.66%
HKSE24,733.45225.640.92%
NASDAQ21,007.35357.211.73%
Nikkei 22540,290.70508.90-1.25%
NZX 50 Index12,684.0445.36-0.36%
S&P 5006,320.9382.921.33%
S&P/ASX 2008,663.701.700.02%
SSE Composite Index3,583.3123.360.66%

Market Movers